iRhythm Technologies’ Zio ambulatory cardiac monitors have the potential to change how doctors screen for atrial fibrillation and other arrythmias by combining miniaturized biosensors and data analytics into a wearable device, CEO Quentin Blackford explains to Bloomberg Intelligence. In this Vanguards of Health Care podcast episode, Blackford sits down with BI analyst Matthew Henriksson for an in-depth interview to talk about iRhythm and how its systems allow patients to be monitored outside of medical offices without disrupting their everyday lives.

Carrum Health Is Rewiring Specialty Care Around Value
52:12

Butterfly Leads the Drive on Semiconductor to Make the Most Out of Ultrasound
43:42

Citizen Health’s Plan to Put an AI Advocate in Every Patient’s Pocket
50:47